Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).
06-14-2020 | ADA 2020 | Conference coverage | Video
06-14-2020 | ADA 2020 | Conference coverage | Video
Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).